Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Heart Failure Reviews
- Vol. 10 (1), 23-29
- https://doi.org/10.1007/s10741-005-2345-1
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?Journal of Cardiac Failure, 2004
- EplerenoneCirculation, 2003
- Aldosterone and Aldosterone Antagonism in Cardiovascular DiseaseHeart Disease, 2003
- Aldosterone Receptor Antagonists for HypertensionDrugs, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])The American Journal of Cardiology, 1996
- Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1995
- Dose-related cardiovascular effects of spironolactoneThe American Journal of Cardiology, 1993
- Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing MetabolitesThe Journal of Clinical Pharmacology, 1989
- Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance ProgramJAMA, 1973